A dire wolf de-extinction debate, CRISPR-GPT for gene editing, and more topped the list of our most popular stories in ...
Modalis Therapeutics Corporation (TOKYO: 4883) today announced that its research article titled "Efficient LAMA1 gene activation by epigenome editing as a therapeutic approach for LAMA2-CMD" has been ...
Here is the full list of the biotech and pharma Startup Battlefield 200 selectees, along with a note on what made us select ...
CRISPR Therapeutics (NASDAQ: CRSP) soared a few years ago, climbing more than 200% from the start of 2020 through early 2021, ...
Morning Overview on MSN
CRISPR boosts a little-known fruit into a big farming win
Goldenberries have long been a niche curiosity, tucked into specialty produce aisles and health food shops while tomatoes and ...
It was the best of times, it was the worst of times for research in 2025. | It was the best of times and it was the worst of times for research in 2025. Medical breakthroughs and stunning discoveries ...
Against this backdrop, a research team led by Dr. Guozhang Kang and Dr. Gezi Li from Henan Agricultural University, China, ...
Now, Musunuru and colleagues are preparing a master clinical protocol to study a CRISPR therapy that's mostly the same as the one they used to treat baby KJ, except they plan to swap out the gene ...
Four autoimmune patients treated to date demonstrate deep B-cell depletion sustained for at least 28 days; initial efficacy ...
Gene editing has rapidly evolved into a transformative class of technologies that allow scientists to precisely insert, ...
Precise tumor diagnosis and treatment require the support of abundant molecular information. However, conventional molecular ...
The first infant to undergo gene-editing therapy has accomplished another first — his first steps. KJ Muldoon is walking and ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback